ASCO: Allogene reports 63% response rate in early trial of off-the-shelf CAR-T in lymphoma

When Allogene reported a 78% response rate to its off-the-shelf CAR-T two weeks ago, the data came with the caveat that it only applied to nine lymphoma patients in an early clinical trial. Now, Allogene is unveiling details on all 22 patients treated so far, and though the response rate isn’t quite as impressive—63% overall—the details could generate some excitement among Wall Street analysts.